OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
- Orchestra Bio: 3 events in the last 90 days
- Orchestra Bio: 3th Acquisition in the last 90 days
- Previous: earlier the same day · OpenAI acquires Orchestra Bio to bring AI agents into drug development
What happened
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
Summary assembled by rule from the sources below